COVID-19 Vaccine Update: As of June 20, our Paramus Vaccination Center will be open Wednesday through Saturday only. The Wellness & Walk-In Care Center at the Garden State Plaza will remain open Monday through Saturday. We are offering vaccines at both locations, by appointment and walk-in, to those ages 12 and older. Click for hours of operation and to make an appointment.
To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.
For more information about any of our clinical trials, please email clinicaltrialsresearch@valleyhealth.com or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Principal Investigator(s):
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Principal Investigator(s):
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Principal Investigator(s):
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Principal Investigator(s):
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Principal Investigator(s):
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Principal Investigator(s):
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Principal Investigator(s):
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator(s):
International Early Lung Cancer Action Program
Principal Investigator(s):
Initiative for Early Lung Cancer Research on Treatment (IELCART)
Principal Investigator(s):
